SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response: 0.5

1. Name and Address of Reporting Person* SVLSF IV, LLC (Last) (First) (Middle) ONE BOSTON PLACE 201 WASHINGTON STREET, SUITE 3900 (Street) BOSTON MA 02108 (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 09/03/2013	3. Issuer Name and Ticker or Trading Symbol SafeStitch Medical, Inc. [ SFES.OB ]
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director X 10% Owner Officer (give title below) Other (specify below)	5. If Amendment, Date of Original Filed (Month/Day/Year)
			6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person X Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock(1)	22,433,674	I	See footnote(1)(5)
Common Stock(2)	22,433,674	I	See footnote(2)(5)
Common Stock(3)	21,814,352	D
Common Stock(4)	619,322	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Series B Convertible Preferred Stock(1)(6)(7)	09/03/2013	(8)	Common Stock	11,549,790	0.4(6)(7)	I	See footnote(1)(5)
Series B Convertible Preferred Stock(2)(6)(7)	09/03/2013	(8)	Common Stock	11,549,790	0.4(6)(7)	I	See footnote(2)(5)
Series B Convertible Preferred Stock(3)(6)	09/03/2013	(8)	Common Stock	11,230,935	0.4(6)	D
Series B Convertible Preferred Stock(4)(7)	09/03/2013	(8)	Common Stock	318,855	0.4(7)	D

1. Name and Address of Reporting Person* SVLSF IV, LLC (Last) (First) (Middle) ONE BOSTON PLACE 201 WASHINGTON STREET, SUITE 3900 (Street) BOSTON MA 02108 (City) (State) (Zip)

1. Name and Address of Reporting Person* SV LIFE SCIENCES FUND IV, L.P. (Last) (First) (Middle) ONE BOSTON PLACE 201 WASHINGTON STREET, SUITE 3900 (Street) BOSTON MA 02108 (City) (State) (Zip)

1. Name and Address of Reporting Person* SV LIFE SCIENCES FUND IV STRATEGIC PARTNERS, L. P. (Last) (First) (Middle) ONE BOSTON PLACE 201 WASHINGTON STREET, SUITE 3900 (Street) BOSTON MA 02108 (City) (State) (Zip)

1. Name and Address of Reporting Person* SV Life Sciences Fund IV (GP), L.P. (Last) (First) (Middle) ONE BOSTON PLACE 201 WASHINGTON STREET, SUITE 3900 (Street) BOSTON MA 02108 (City) (State) (Zip)

Explanation of Responses:

1. These shares are owned directly by SV Life Sciences Fund IV, L.P. ("SVLS IV LP") and SV Life Sciences Fund IV Strategic Partners, L.P. ("Strategic Partners"). SV Life Sciences Fund IV (GP), L.P. ("SVLS IV GP"), the general partner of SVLS IV LP and Strategic Partners, may be deemed to share voting and dispositive power over the shares held by SVLS IV LP and Strategic Partners. SVLS IV GP disclaims beneficial ownership of shares held by SVLS IV LP and Strategic Partners except to the extent of any pecuniary interest therein.

2. These shares are owned directly by SVLS IV LP and Strategic Partners. SVLSF IV, LLC, the general partner of SVLS IV GP, may be deemed to share voting and dispositive power over the shares held by SVLS IV LP and Strategic Partners. SVLSF IV, LLC disclaims beneficial ownership of shares held by SVLS IV LP and Strategic Partners except to the extent of any pecuniary interest therein.

3. These shares are held directly by SVLS IV LP.

4. These shares are held directly by Strategic Partners.

5. SVLS IV LP and Strategic Partners (each a "Fund", or collectively the "Funds") may be deemed to beneficially own the shares held by each other Fund because of certain contractual relationships among the Funds and their affiliates. The Funds disclaim beneficial ownership of shares held by any other Fund except to the extent of any pecuniary interest therein.

6. On September 3, 2013, SafeStitch Medical, Inc. (the "Issuer") sold and issued to SVLS IV LP, in a privately negotiated transaction pursuant to a securities purchase agreement, an aggregate of 1,123,093.5 shares of the Issuer's Series B Convertible Preferred Stock at a purchase price of $4.00 per share. Upon the filing of an Amendment to the Issuer's Certificate of Incorporation with the State of Delaware, each share of the Issuer's Series B Convertible Preferred Stock will automatically convert into ten (10) shares of the Issuer's common stock.

7. On September 3, 2013, the Issuer sold and issued to Strategic Partners, in a privately negotiated transaction pursuant to a securities purchase agreement, an aggregate of 31,885.5 shares of the Issuer's Series B Convertible Preferred Stock at a purchase price of $4.00 per share. Upon the filing of an Amendment to the Issuer's Certificate of Incorporation with the State of Delaware, each share of the Issuer's Series B Convertible Preferred Stock will automatically convert into ten (10) shares of the Issuer's common stock.

8. The Series B Convertible Preferred Stock has no expiration date.

	/s/ Thomas B. Rosedale (pursuant to power of attorney)	09/11/2013
	/s/ Thomas B. Rosedale (pursuant to power of attorney)	09/11/2013
	/s/ Thomas B. Rosedale (pursuant to power of attorney)	09/11/2013
	/s/ Thomas B. Rosedale (pursuant to power of attorney)	09/11/2013
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

LIMITED POWER OF ATTORNEY

OF

SVLSF IV, LLC



	This statement confirms that the undersigned has authorized and designated each
of Suzanne Hamel and Thomas B. Rosedale his attorneys-in-fact to (i) prepare, execute
and file on behalf of the undersigned Form ID or any other necessary documents or forms
in order to obtain access codes (including, without limitation, CIK and CCC codes) for
the undersigned to permit filing on EDGAR, and (ii) prepare, execute and file on behalf
of the undersigned all Forms 3, 4 and 5 (including any amendments thereto) that the
undersigned may be required to file with the U.S. Securities and Exchange Commission
as a result of the undersigned's ownership of or transactions in securities of a public
reporting company or by virtue of the undersigned holding board of director or executive
officer positions with a public reporting company.  The authority of such attorneys under
this Power of Attorney shall continue until the undersigned is no longer required to file
Forms 3, 4 and 5 with the U.S. Securities and Exchange Commission, unless earlier
revoked in writing.  The undersigned acknowledges that such attorneys are not assuming
any of the undersigned's responsibilities to comply with the requirements of Section 16 of
the Securities Exchange Act of 1934, as amended, or any of the undersigned's liabilities
for failure to comply with such requirements.



       					SVLSF IV, LLC


Date: August 22, 2013	 		  _/s/ Denise W. Marks_________________
						  Name: Denise W. Marks
						  Title: Member

LIMITED POWER OF ATTORNEY

OF

SV LIFE SCIENCES FUND IV, L.P.



	This statement confirms that the undersigned has authorized and designated each
of Suzanne Hamel and Thomas B. Rosedale his attorneys-in-fact to (i) prepare, execute
and file on behalf of the undersigned Form ID or any other necessary documents or forms
in order to obtain access codes (including, without limitation, CIK and CCC codes) for
the undersigned to permit filing on EDGAR, and (ii) prepare, execute and file on behalf
of the undersigned all Forms 3, 4 and 5 (including any amendments thereto) that the
undersigned may be required to file with the U.S. Securities and Exchange Commission
as a result of the undersigned's ownership of or transactions in securities of a public
reporting company or by virtue of the undersigned holding board of director or executive
officer positions with a public reporting company.  The authority of such attorneys under
this Power of Attorney shall continue until the undersigned is no longer required to file
Forms 3, 4 and 5 with the U.S. Securities and Exchange Commission, unless earlier
revoked in writing.  The undersigned acknowledges that such attorneys are not assuming
any of the undersigned's responsibilities to comply with the requirements of Section 16 of
the Securities Exchange Act of 1934, as amended, or any of the undersigned's liabilities
for failure to comply with such requirements.



					SV LIFE SCIENCES FUND IV, L.P.

					By: SV Life Sciences Fund IV (GP), L.P.,
					its Sole General Partner
					By: SVLSF IV, LLC, its sole General
					Partner



Date: August 22, 2013	 		  _/s/ Denise W. Marks_________________
						  Name: Denise W. Marks
						  Title: Member

LIMITED POWER OF ATTORNEY

OF

SV LIFE SCIENCES FUND IV STRATEGIC PARTNERS, L.P.



	This statement confirms that the undersigned has authorized and designated each
of Suzanne Hamel and Thomas B. Rosedale his attorneys-in-fact to (i) prepare, execute
and file on behalf of the undersigned Form ID or any other necessary documents or forms
in order to obtain access codes (including, without limitation, CIK and CCC codes) for
the undersigned to permit filing on EDGAR, and (ii) prepare, execute and file on behalf
of the undersigned all Forms 3, 4 and 5 (including any amendments thereto) that the
undersigned may be required to file with the U.S. Securities and Exchange Commission
as a result of the undersigned's ownership of or transactions in securities of a public
reporting company or by virtue of the undersigned holding board of director or executive
officer positions with a public reporting company.  The authority of such attorneys under
this Power of Attorney shall continue until the undersigned is no longer required to file
Forms 3, 4 and 5 with the U.S. Securities and Exchange Commission, unless earlier
revoked in writing.  The undersigned acknowledges that such attorneys are not assuming
any of the undersigned's responsibilities to comply with the requirements of Section 16 of
the Securities Exchange Act of 1934, as amended, or any of the undersigned's liabilities
for failure to comply with such requirements.



					SV LIFE SCIENCES FUND IV
					STRATEGIC PARTNERS, L.P.

					By: SV Life Sciences Fund IV (GP), L.P.,
					its Sole General Partner
					By: SVLSF IV, LLC, its sole General
					Partner


Date: August 22, 2013	 		  _/s/ Denise W. Marks_________________
						  Name: Denise W. Marks
						  Title: Member

LIMITED POWER OF ATTORNEY

OF

SV LIFE SCIENCES FUND IV (GP), L.P.



	This statement confirms that the undersigned has authorized and designated each
of Suzanne Hamel and Thomas B. Rosedale his attorneys-in-fact to (i) prepare, execute
and file on behalf of the undersigned Form ID or any other necessary documents or forms
in order to obtain access codes (including, without limitation, CIK and CCC codes) for
the undersigned to permit filing on EDGAR, and (ii) prepare, execute and file on behalf
of the undersigned all Forms 3, 4 and 5 (including any amendments thereto) that the
undersigned may be required to file with the U.S. Securities and Exchange Commission
as a result of the undersigned's ownership of or transactions in securities of a public
reporting company or by virtue of the undersigned holding board of director or executive
officer positions with a public reporting company.  The authority of such attorneys under
this Power of Attorney shall continue until the undersigned is no longer required to file
Forms 3, 4 and 5 with the U.S. Securities and Exchange Commission, unless earlier
revoked in writing.  The undersigned acknowledges that such attorneys are not assuming
any of the undersigned's responsibilities to comply with the requirements of Section 16 of
the Securities Exchange Act of 1934, as amended, or any of the undersigned's liabilities
for failure to comply with such requirements.



 					SV LIFE SCIENCES FUND IV (GP), L.P.

					By: SVLSF IV, LLC, its sole General
					Partner


Date: August 22, 2013	 		  _/s/ Denise W. Marks_________________
						  Name: Denise W. Marks
						  Title: Member